DALLAS--(BUSINESS WIRE)--HemoBioTech, Inc. (OTC BB: HMBT), a biopharmaceutical company focused on developing the first viable substitute for human blood, has retained the Investor Relations Group, Inc. (IRG), based in New York City, to serve as its financial relations and corporate communications firm.
